MRK

SEC source: 0001127602-23-014025 · form4.xml · derivative · entry 6

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 66,163 shares

Expires 2027-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.

SEC source: 0001127602-23-014025 · form4.xml · nonDerivative · entry 2

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,492.854

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.0000 to $115.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-014025 · form4.xml · nonDerivative · entry 1

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,655.854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 9

Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,599.325

F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b).

SEC source: 0001127602-23-012932 · form4.xml · derivative · entry 9

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 66,163 shares

Expires 2027-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F9 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.

SEC source: 0001127602-23-012932 · form4.xml · derivative · entry 8

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 67,892 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021.

SEC source: 0001127602-23-012932 · form4.xml · nonDerivative · entry 4

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.0000 to $115.3300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-012932 · form4.xml · nonDerivative · entry 3

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,892

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.0000 to $115.1900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-012932 · form4.xml · nonDerivative · entry 2

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-012932 · form4.xml · nonDerivative · entry 1

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,892

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-011940 · form4.xml · derivative · entry 2

GLOCER THOMAS H · CIK 0001140799 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,408.8466

Underlying: Common Stock · 422.9721 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-011949 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,477.8377

Underlying: Common Stock · 281.9814 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-011944 · form4.xml · derivative · entry 2

Seidman Christine E · CIK 0001805745 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,339.612

Underlying: Common Stock · 76.37 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-011952 · form4.xml · derivative · entry 2

Coe Mary Ellen · CIK 0001691304 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,499.1457

Underlying: Common Stock · 304.1744 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 8

Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,596.325

F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b).

SEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 7

Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,631.325

F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b).

SEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 6

Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,495.325

F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b).

SEC source: 0001127602-23-005484 · form4.xml · nonDerivative · entry 1

Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,284.325

SEC source: 0001127602-23-005037 · form4.xml · nonDerivative · entry 1

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,085.145

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.1000 to $109.1050, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-004855 · form4.xml · derivative · entry 3

Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,205 shares

Expires 2023-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 2/10/2021, 2/10/2022 and 2/10/2023.

SEC source: 0001127602-23-004855 · form4.xml · nonDerivative · entry 2

Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,091.892

F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-004855 · form4.xml · nonDerivative · entry 1

Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,504.892

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-004321 · form4.xml · nonDerivative · entry 1

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,900.145

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.0000 to $107.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-003923 · form4.xml · nonDerivative · entry 1

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,900.145

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.2350 to $104.2850, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-003562 · form4.xml · derivative · entry 3

Zachary Jennifer · CIK 0001737231 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 75,436 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021.

SEC source: 0001127602-23-003562 · form4.xml · nonDerivative · entry 2

Zachary Jennifer · CIK 0001737231 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,919.941

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.0200 to $103.5450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-003562 · form4.xml · nonDerivative · entry 1

Zachary Jennifer · CIK 0001737231 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,355.941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-002193 · form4.xml · nonDerivative · entry 1

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,995

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

SEC source: 0001127602-23-002197 · form4.xml · nonDerivative · entry 1

Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,989.93

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-002204 · form4.xml · nonDerivative · entry 1

Litchfield Caroline · CIK 0001854928 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,186.6811

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-002213 · form4.xml · nonDerivative · entry 1

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,500.379

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-002223 · form4.xml · nonDerivative · entry 1

Li Dean Y · CIK 0001837016 · Executive VP & President, MRL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,933.432

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-002217 · form4.xml · nonDerivative · entry 1

Davis Robert M · CIK 0001363076 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,816.757

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

SEC source: 0001127602-23-002228 · form4.xml · nonDerivative · entry 1

Zachary Jennifer · CIK 0001737231 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,919.941

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-002241 · form4.xml · nonDerivative · entry 1

MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,336.145

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

SEC source: 0001127602-23-002247 · form4.xml · nonDerivative · entry 1

Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,948.972

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

SEC source: 0001127602-23-002251 · form4.xml · nonDerivative · entry 1

Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,007.757

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

SEC source: 0001127602-23-002257 · form4.xml · nonDerivative · entry 1

Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,821.881

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022.

SEC source: 0001127602-23-001274 · form4.xml · derivative · entry 9

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,994 shares

Expires 2026-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F10 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

SEC source: 0001127602-23-001274 · form4.xml · nonDerivative · entry 6

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,500

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.3700 to $114.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-001274 · form4.xml · nonDerivative · entry 5

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,202

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.3500 to $114.3500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-001274 · form4.xml · nonDerivative · entry 4

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,418

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.3200 to $113.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-001274 · form4.xml · nonDerivative · entry 3

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,358

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.2800 to $112.2100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-001274 · form4.xml · nonDerivative · entry 2

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,896

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.2600 to $111.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

SEC source: 0001127602-23-001274 · form4.xml · nonDerivative · entry 1

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,494

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-000135 · form4.xml · derivative · entry 2

Coe Mary Ellen · CIK 0001691304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,083.9243

Underlying: Common Stock · 292.9247 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-000147 · form4.xml · derivative · entry 2

GLOCER THOMAS H · CIK 0001140799 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,420.4065

Underlying: Common Stock · 405.5881 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-000152 · form4.xml · derivative · entry 2

Seidman Christine E · CIK 0001805745 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,192.677

Underlying: Common Stock · 73.2312 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-000159 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,421.0783

Underlying: Common Stock · 270.3921 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 5

Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,484.325

F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b).